Ix Biopharma Ltd. · SGX:42C
Ix Biopharma — Investor Presentation (March 2024)
13 slides from Ix Biopharma's investor presentation, March 2024
Slide 1: iX Biopharma Ltd Update for Shareholders, March 2024
iX Biopharma Ltd Update for Shareholders, March 2024
Slide 2: Agenda
AGENDA 1) Overview of iX Technologies 2) Our Growth Drivers GLP-1 Wafer Wafermine Healthspan Products 3) Fast Track to Monetisation 2
Slide 3: Advanced Drug Delivery Technologies
Advanced Drug Delivery Technologies 1) WaferiX - optimised for sublingual administration Advantages of our Freeze-Dried Wafers of small molecules Patented matrix formulation and proprietary manufacturing process creates highly porous, amorphous, non-ionic wafers Fig. Patented formulation and proprie
Slide 4: Our Growth Drivers
Our Growth Drivers 1) iXB 401, GLP-1 sublingual wafer to treat diabetes/obesity 2) Out-license Wafermine for a) Complex Regional Pain Syndrome (CRPS) & b) Depression 3) Ramp up commercialisation of Healthspan products 4
Slide 5: Focusing on the Booming GLP-1 Drug Market
Focusing on the Booming GLP-1 Drug Market GLP-1 peptides are hormones and neuromodulators. Approved GLP-1 drugs like Ozempic & Wegovy (semaglutide), Mounjaro (tirzepatide) & Trulicity (dulaglutide) have numerous benefits: Glucose control in type 2 diabetes, significant weight loss in obesity, and ca
Slide 6: Surging Deal Flow
Surging Deal Flow There has been a surge of substantial acquisitions and licensing deals by big pharma vying for dominance a) Eli Lilly acquired Versanis Bio for $1.93 billion for monoclonal antibody, bimagrumab (P2b ongoing), used in combination with semaglutide to reduce weight while preserving mu
Slide 7: iXB 401, Sublingual Semaglutide (GLP-1 agonist) wafer
iXB 401, Sublingual Semaglutide (GLP-1 agonist) wafer Semaglutide (Ozempic, Wegovy) mimics the action of the body’s natural GLP-1 peptide hormone, which manages blood sugar levels and helps reduce hunger and food iXB 401 targets 3 absorption sites, not just the stomach intake after a meal Sublingu
Slide 8: Wafermine, Out-licensing for CRPS & Depression
Wafermine, Out-licensing for CRPS & Depression Complex Regional Pain Syndrome (CRPS) Treatment Resistant Depression (TRD) CRPS is a rare condition 1/3 of patients with major depressive disorder do not respond to current treatments, meaning they Affected individuals experience excruciating, hav
Slide 9: Our Approach to Healthspan
Our Approach to Healthspan We know we are living longer (Lifespan) but not necessarily healthier (Healthspan). The world is now wishing to live not only longer but also healthier, free from age-associated chronic conditions including cancer, dementia, and heart disease; in short for a better quality
Slide 10: NAD+ Wafers Enhance Healthspan
NAD+ Wafers Enhance Healthspan iX’s sublingual NAD+ wafers Leverage NADiX proprietary technology to stabilise and NAD+ is an unstable molecule, deliver pure NAD+ directly as nanoparticles into the body degraded in GI tract Shown to significantly increase intracellular NAD+ levels Avoid the nee
Slide 11: Fast Track to Monetisation
Fast Track to Monetisation Out-Licensing Opportunities Out-Licensing Opportunities IMMEDIATE Benefits of out-licensing: 1) Wafermine, Out-license for CRPS and/or Depression Generate revenue (upfront fees, milestone sublingual ketamine wafer development payments, sales royalties) Partner will f
Slide 12: Disclaimer
DISCLAIMER The information in this presentation has not been independently verified. This presentation is strictly private & confidential, & is meant solely for your information only. Nothing in this presentation is or shall be considered to be an offer for the solicitation, sale or subscription of
Slide 13: Thank You
Thank You 13 Mitochondria- Cell’s Energy Factory, Powered by NAD+